Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05546827 · ClinicalTrials.gov registry record · Phase 2

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

A Phase 2 study of Sinonasal Melanoma and Anorectal Melanoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT05546827 is a Phase 2 study of Sinonasal Melanoma and Anorectal Melanoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05546827, a Phase 2 study of Sinonasal Melanoma and Anorectal Melanoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes

Interventions

  • PROCEDURE Surgical resection

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-09-23
Est. Completion 2028-07-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT05546827

The ClinicalTrials.gov registry entry for NCT05546827 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sinonasal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Surgical resection is the first listed.

NCT05546827 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05546827 about?

NCT05546827 is a clinical study titled "Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma". The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes

What is the current status of trial NCT05546827?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-09-23. Estimated completion is 2028-07-31.

What conditions does trial NCT05546827 study?

This clinical trial studies the following conditions: Sinonasal Melanoma, Anorectal Melanoma.

What interventions are being tested in trial NCT05546827?

The interventions under investigation include: Surgical resection (PROCEDURE).

Who is sponsoring clinical trial NCT05546827?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05546827 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.